Unveiling 4 Analyst Insights On Theravance Biopharma
Portfolio Pulse from Benzinga Insights
Theravance Biopharma (NASDAQ:TBPH) has received mixed analyst ratings over the past three months, with a recent average price target of $12.25, down from $15.00. Analysts have adjusted their ratings and price targets in response to market dynamics and company performance. Theravance Biopharma is a biopharmaceutical company focused on organ-selective medicines, with a recent revenue growth rate of 3.69% and a net margin of -115.94%.
September 16, 2024 | 12:00 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Theravance Biopharma has received mixed analyst ratings, with a recent average price target of $12.25, down from $15.00. Analysts have adjusted their ratings and price targets in response to market dynamics and company performance.
The mixed analyst ratings and lowered price targets suggest uncertainty about Theravance Biopharma's short-term performance. The decrease in the average price target indicates a less optimistic outlook, but the presence of bullish ratings suggests some confidence in the company's potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100